Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia

• US 6,117,860 A
• Filed: 07/23/1997
• Issued: 09/12/2000
• Est. Priority Date: 08/04/1994
• Status: Expired due to Term

• Current Assignee: Pherin Pharmaceuticals, Inc.
• Original Assignee: Pherin Pharmaceuticals, Inc.
• Inventors: Berliner, David L., Jennings-White, Clive L., Adams, Nathan W., Monti-Bloch, Luis
• Primary Examiner(s): JORDAN, KIMBERLY R
• Application Number:
  US08/899,094
• Time in Patent Office: 1,147 Days
• Field of Search: 514/177, 514/178, 514/179, 514/181, 514/182
• US Class Current: 514/177
• CPC Class Codes: A61K 31/568 substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: C07J 13/002 with double bond in position 13 (17)
• CPC Class Codes: C07J 13/005 with double bond in position 16 (17)
• CPC Class Codes: C07J 13/007 with double bond in position 17 (20)
• CPC Class Codes: C07J 21/00 Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
• CPC Class Codes: C07J 3/00 Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
• CPC Class Codes: C07J 41/0005 the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
• CPC Class Codes: C07J 7/0005 not substituted in position 21
• CPC Class Codes: C07J 7/002 not substituted in position 16
• CPC Class Codes: C07J 71/0005 Oxygen-containing hetero ring
• CPC Class Codes: C07J 71/001 Oxiranes
• CPC Class Codes: C07J 9/00 Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Abstract

The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

Claims

1. A method of treating paroxistic tachycardia in an individual, said method comprising:

providing a steroid which binds to receptors on the surface of nasal neuroepithelial cells of said individual wherein said cells are part of tissue other than olfactory epithelia; and

,

administering said effective amount of said steroid within a nasal passage of said individual such that said steroid binds specifically to said receptors and results in alleviation of symptoms of said disorder in said individual.

2. The method of claim 1 wherein said neuroepithelial cell is located within a vomeronasal organ of said individual.

3. The method of claim 2 wherein said steroid comprises a pregnane of the formula:

##STR600## wherein P₁ is selected from the group consisting of oxo, α

-(β

-) hydroxy, α

-(β

-) acetoxy, α

-(β

-) propionoxy, α

-(β

-) methoxy, α

-(β

-) lower acyloxy, α

-(β

-) lower alkyloxy, and α

-(β

-) benzoyloxy;

P₂ is selected from the group consisting of methyl, hydroxymethyl, acyloxymethyl, alkoxymethyl, lower alkyl, hydroxyalkyl, acyloxyalkyl, and alkoxylalkyl;

P₃ is selected from the group consisting of hydrogen, oxo, halo, hydroxy, alkoxy, and acyloxy;

P₄ through P₁₂ may each be, independently, hydrogen, halo, methyl, or halo-, dihalo- or perhalomethyl;

P₁₃ is hydrogen, methyl, methylene, halo-substituted methyl or halo-substituted methylene, ethyl, ethylenyl, acetylenyl, methyl-methylenyl or methyl-methinyl; and

"a", "b", "c", "d", "e", "h", "i", "j" and "k" are alternative sites for optional double bonds and "j" or "k" may also be triple bonds; and

when P₂ is methyl and P₃ is β

-hydroxy, P₂ and P₃ may be joined to form a cyclic ether.

4. A method according to claim 3 wherein "b" is a double bond.

5. A method according to claim 4 wherein "e" or "d" is a double bond.

6. A method according to claims 3 wherein "a" and "c" are double bonds.

7. A method according to claim 3 wherein "h" is an optional double bond, and "i" and "j" are absent.

8. A method according to claim 3 wherein is a double "j" is a double bond.

9. A method according to claim 3 wherein "j" is a triple bond.

10. The method of claim 2 wherein said steroid comprises a 19-nor-pregnane of the formula:

##STR601## wherein P₁ is oxo, α

- or A-hydroxy, α

- or β

-acetoxy, α

- or β

-propionoxy, α

- or β

-lower alkoxy, α

- or β

-lower acyloxy or α

- or β

-benzyloxy;

"a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "m", and "n" are alternative sites for optional double bonds, and "k" may be absent or present with "j" to form a triple bond;

P₂ is a hydroxy, hydrogen, lower alkoxy of 1 to 6 carbon atoms, or P₂ is absent;

P₃ is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;

P₄ is methyl or ethyl;

P₅ is hydrogen, methyl or halo;

P₆ is hydrogen or methyl;

R'"'"' and R" are independently, hydrogen or halo, or are absent.

11. A method according to claim 10 wherein "a", "e" and "d" are double bonds.

12. A method according to claim 11 wherein "h" is a double bond.

13. A method according to claim 11 wherein "g" is a double bond.

14. A method according to claim 13 wherein "n" is a double bond.

15. A method according to claim 10 wherein "d" is a double bond.

16. A method according to claim 15 wherein "b" is a 15 double bond.

17. A method according to claim 15 wherein "c" is a double bond.

18. A method according to claim 17 wherein "f" is a double bond.

19. The method of claim 2 wherein said steroid is an estrene which has the formula:

##STR602## wherein R₁ is selected from the group consisting essentially of one or two hydrogen atoms, methyl, methylene, and one or, two halo atoms;

R₂ is absent or is selected from the group consisting essentially of hydrogen and methyl;

R₃ is selected from the group consisting essentially of oxo, hydroxy, lower alkoxy, lower acyloxy, benzoyl, cypionyl, glucuronide and sulfonyl;

R₄ is selected from the group consisting essentially of hydrogen, hydroxy, lower alkoxy, lower acyloxy and halo;

R₅ is absent or is selected from the group consisting essentially of hydrogen, hydroxy, lower alkoxy and lower acyloxy;

R₆ is a hydrogen or a halo; and

"a" represents optional aromatic unsaturation of ring A of said steroid, or "b", "c", and "d" are each optional double bonds;

"e", "f", "g", "h", "i" and "j" are each optional double bonds; and

"e" may also form an epoxy ring with C₁₆ and C₁₇.

20. A method according to claim 19 wherein "a" is present and "g", "h" or "i" are optional double bonds.

21. A method according to claim 20 wherein "h" and "i" are both double bonds.

22. A method according to claim 19 wherein "b" is a double bond.

23. A method according to claim 19 wherein "j" is a double bond.

24. A method according to claim 19 wherein "c" is a double bond.

25. A method according to claim 19 wherein "c" and "d" are double bonds.

26. A method according to claim 19 wherein R₂ is methyl and "e" is a double bond.

27. A method according to claim 19 wherein said steroid is selected from the group consisting of Estra-4,16-dien-3-one;

Estra-1,3,5(10),16-tetraene-3-ol;

10 Estra-4,16-dien-3α

-ol;

Estra-4,9(10),16-triene-3-one;

Estra-1,3,5(10),16-tetraen-3-ol-6-one;

3-Methoxyl-estra-2,5(10),16-triene;

Estra-5(10),16-dien-3α

-ol; and

Estra-1,3,5(10),16-tetraen-3,6α

-diol.

28. A method according to claim 19 wherein R₅ is methyl.

29. A method according to claim 28 wherein said steroid is selected from the group consisting essentially of Estra-1,3,5(10)-trien-3-ol;

Estra-1,3,5(10),6-tetraen-3-ol; and

Estra-1,3,5(10),7-tetraen 3-ol.

30. A method according to claim 19 wherein R₁ is methylene.

31. A method according to claim 30 wherein said steroid is 17-Methylene-estra-1,3,5(10),6,8(9)hexaen-3-ol.

32. A method according to claim 19 wherein R₁ is methylene or a single hydrogen and R₂ is methyl.

33. A method according to claim 19 wherein "f" is a double bond and R₂ is methyl.

34. The method of claim 33 wherein at least one Estrene steroid is selected from the group consisting of 1,3,5(10),16-Estratetraen-3-methyl ether, ol,1,3,S(10),16-Estratetraen-3-ol 1,3,5(10),16-Estratetraen-3-yl acetate, and 1,3,5 (10), 16-Estratetraen-3-yl propionate.

35. The method of claim 33 wherein the Estrene steroid is 1,3,5(10), 16-Estratetraen-3-ol.

36. A method of claim 19 wherein the estrene is estra-4,16-dien-10β

-ol-3-one.

37. A method according to claim 19 wherein "e" forms an epoxy ring with C₁₆ and C₁₇.

38. A method according to claim 37 wherein said estrene is 16α

,17α

-epoxy-estra-1,3,5(10)-trien-3-ol.

39. A method according to claim 37 wherein said estrene is 16α

,17α

-epoxyestr-4-en-10β

-ol-3-one.

40. The method of claim 2 wherein said steroid is an androstane of the formula:

##STR603## wherein P₁ is selected from the group consisting of oxo, α

-(β

-) hydroxy, α

-(β

-) acetoxy, α

-(β

-) propionoxy, α

-(β

--);

methoxy, α

-(β

-) lower acyloxy, α

-(β

-) lower alkyloxy, and α

-(β

-) benzoyloxy;

P₂ is selected from the group consisting of methyl, hydroxymethyl, acyloxymethyl, alkoxymethyl, lower alkyl, hydroxyalkyl, acyloxyalkyl, and alkoxylalkyl;

P₃ is absent or is selected from the group consisting of methyl, hydroxymethyl, acyloxymethyl, alkoxymethyl, lower alkyl, hydroxyalkyl, acyloxyalkyl, and alkoxylalkyl;

P₄ is selected from the group consisting of hydrogen, oxo, halo, hydroxy, alkoxy, and acyloxy;

P₅ represents one or 2 substituents, wherein P₅ comprises one or two hydrogen atoms, methyl, methylene, or one or two halo atoms;

P₆ is hydrogen or halo; and

"a", "b", "c", "d", "e", "f" and "h" are alternative sites for optional double bonds.

41. A method according to claim 40 wherein "b" is a double bond.

42. A method according to claim 41 wherein "e" or "d" is a double bond.

43. A method according to claim 40 wherein "a" and "c" are double bonds.

44. A method according to claim 40 wherein P₃ is methyl, "h" is an optional double bond, and P₅ is methylene or one or two hydrogen atoms.

45. A method according to claim 40 wherein P₃ is methyl and "h" is a double bond.

46. A method according to claim 45 wherein said steroid is selected from the group consisting of Androsta-5,16-dien-3α

-ol, Androsta-4,6,16-triene-3-one;

Androsta-4,16-dien-3,6-dione;

19-Hydroxy-androsta-4,16-dien-3-one;

3-Methoxy-androsta-3,5,16-triene; and

6˜

-Hydroxy-androsta-4-16-dien-3-one.

47. A method according to claim 40 wherein P₃ is methyl.

48. A method according to claim 47 wherein said steroid is Androst-4-en-3-one.

49. A method according to claim 40 wherein P₅ is methylene.

50. A method according to claim 49 wherein said steroid is selected from the group consisting of 20-Homo-androsta-4,17-dien-3˜

-ol;

20-Homo androsta-4,17-dien-3β

-ol; and

20-Homo androsta-4,17-dien-3,6-dione.

51. A method according to claim 40 wherein P₅ is methyl and "f" is a double bond.

52. The method of claim 40 wherein "a" or "b" is a double bond.

53. she method of claim 40 wherein at least one Androstane steroid is selected from the group consisting of Androsta-4, 516-dien-3-one, Androsta-4,16-dien-3α

-ol and Androsta-4,16-dien-3β

-ol.

54. The method of claim 53 wherein said steroid is Androsta-4,16-dien-3-one.

55. A method according to claim 53 wherein said steroid is Androsta-4,16-dien-3β

-ol.

56. A method of claim 2 wherein said steroid is a 19-norcholane of the formula:

##STR604## wherein P₁ is oxo, α

- or β

-hydroxy, α

- or β

-acetoxy, or β

-propionoxy, α

- or β

-lower alkoxy, α

- or β

-lower acyloxy or α

- or β

-benzyloxy;

"a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "m", "s" and "n" are alternative sites for optional double bonds, and may be absent or present with "j" to form a triple bond;

P₂ is hydroxy, hydrogen, lower alkoxy of 1 to 6 carbon atoms, or P₂ is absent;

P₃ is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;

P₄ is methyl or ethyl;

each P₅ and P₇ is independently is hydrogen, methyl or halo;

P₆ is hydrogen or methyl;

R'"'"' and R" are independently, hydrogen halo, or are absent, or together form ═

CH₂ ;

and q is an integer from 0 to 2;

on the surface of nasal neuroepithelial cell of said individual wherein said cell is a part of tissue other than olfactory epithelia; and

administering said 19-nor-cholane derivative within a nasal passage of said individual such that said 19-nor-cholane derivative binds specifically to said receptor and results in an alteration of hypothalamic function of said individual.

57. A method according to claim 56 wherein "a", "e" and "d" are double bonds.

58. A method according to claim 57 wherein "h" is a double bond.

59. A method according to claim 57 wherein "g" is a double bond.

60. A method according to claim 59 wherein "n" is a double bond.

61. A method according to claim 56 wherein "d" is a double bond.

62. A method according to claim 61 wherein "b" is a double bond.

63. A method according to claim 56 wherein "c" is a double bond.

64. A method according to claim 56 wherein "s" is a double bond.

65. The method of claim 1 wherein the amount of said steroid that is administered is at least about 100 picograms, but no more than about 100 micrograms.

66. The method of claim 65 wherein the amount of said steroid that is administered is at least about 1 nanogram, but no more than about 10 micrograms.

67. The method of claim 66 wherein the amount of said steroid that is administered is at least about 10 nanograms, but no more than about 1 microgram.

68. The method of claim 65 wherein said steroid is administered in an ointment.

69. The method of claim 65 wherein said steroid is administered in a liquid.

70. The method of claim 65 wherein said steroid is administered by aerosol.